Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer

Sudhanshu Shukla, Xiang Zhang, Yashar S. Niknafs, Lanbo Xiao, Rohit Mehra, Marcin Cieślik, Ashley Ross, Edward Schaeffer, Bhavna Malik, Shuling Guo, Susan M. Freier, Huynh Hoa Bui, Javed Siddiqui, Xiaojun Jing, Xuhong Cao, Saravana M. Dhanasekaran, Felix Y. Feng, Arul M. Chinnaiyan, Rohit Malik

Research output: Contribution to journalArticle

Abstract

Rapid advances in the discovery of long noncoding RNAs (lncRNAs) have identified lineage- and cancer-specific biomarkers that may be relevant in the clinical management of prostate cancer (PCa). Here we assembled and analyzed a large RNA-seq dataset, from 585 patient samples, including benign prostate tissue and both localized and metastatic PCa to discover and validate differentially expressed genes associated with disease aggressiveness. We performed Sample Set Enrichment Analysis (SSEA) and identified genes associated with low versus high Gleason score in the RNA-seq database. Comparing Gleason 6 versus 9+ PCa samples, we identified 99 differentially expressed genes with variable association to Gleason grade as well as robust expression in prostate cancer. The top-ranked novel lncRNA PCAT14, exhibits both cancer and lineage specificity. On multivariate analysis, low PCAT14 expression independently predicts for BPFS (P = .00126), PSS (P = .0385), and MFS (P = .000609), with trends for OS as well (P = .056). An RNA in-situ hybridization (ISH) assay for PCAT14 distinguished benign vs malignant cases, as well as high vs low Gleason disease. PCAT14 is transcriptionally regulated by AR, and endogenous PCAT14 overexpression suppresses cell invasion. Thus, Using RNA-sequencing data we identify PCAT14, a novel prostate cancer and lineage-specific lncRNA. PCAT14 is highly expressed in low grade disease and loss of PCAT14 predicts for disease aggressiveness and recurrence.

Original languageEnglish (US)
Pages (from-to)489-499
Number of pages11
JournalNeoplasia (United States)
Volume18
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Long Noncoding RNA
Prostatic Neoplasms
Biomarkers
RNA
Genes
RNA Sequence Analysis
Neoplasm Grading
Nucleic Acid Databases
Tumor Biomarkers
In Situ Hybridization
Prostate
Multivariate Analysis
Recurrence
Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

Shukla, S., Zhang, X., Niknafs, Y. S., Xiao, L., Mehra, R., Cieślik, M., ... Malik, R. (2016). Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia (United States), 18(8), 489-499. https://doi.org/10.1016/j.neo.2016.07.001

Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. / Shukla, Sudhanshu; Zhang, Xiang; Niknafs, Yashar S.; Xiao, Lanbo; Mehra, Rohit; Cieślik, Marcin; Ross, Ashley; Schaeffer, Edward; Malik, Bhavna; Guo, Shuling; Freier, Susan M.; Bui, Huynh Hoa; Siddiqui, Javed; Jing, Xiaojun; Cao, Xuhong; Dhanasekaran, Saravana M.; Feng, Felix Y.; Chinnaiyan, Arul M.; Malik, Rohit.

In: Neoplasia (United States), Vol. 18, No. 8, 01.08.2016, p. 489-499.

Research output: Contribution to journalArticle

Shukla, S, Zhang, X, Niknafs, YS, Xiao, L, Mehra, R, Cieślik, M, Ross, A, Schaeffer, E, Malik, B, Guo, S, Freier, SM, Bui, HH, Siddiqui, J, Jing, X, Cao, X, Dhanasekaran, SM, Feng, FY, Chinnaiyan, AM & Malik, R 2016, 'Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer', Neoplasia (United States), vol. 18, no. 8, pp. 489-499. https://doi.org/10.1016/j.neo.2016.07.001
Shukla, Sudhanshu ; Zhang, Xiang ; Niknafs, Yashar S. ; Xiao, Lanbo ; Mehra, Rohit ; Cieślik, Marcin ; Ross, Ashley ; Schaeffer, Edward ; Malik, Bhavna ; Guo, Shuling ; Freier, Susan M. ; Bui, Huynh Hoa ; Siddiqui, Javed ; Jing, Xiaojun ; Cao, Xuhong ; Dhanasekaran, Saravana M. ; Feng, Felix Y. ; Chinnaiyan, Arul M. ; Malik, Rohit. / Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. In: Neoplasia (United States). 2016 ; Vol. 18, No. 8. pp. 489-499.
@article{0b2db919d75247bca7732d06ae5b28f6,
title = "Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer",
abstract = "Rapid advances in the discovery of long noncoding RNAs (lncRNAs) have identified lineage- and cancer-specific biomarkers that may be relevant in the clinical management of prostate cancer (PCa). Here we assembled and analyzed a large RNA-seq dataset, from 585 patient samples, including benign prostate tissue and both localized and metastatic PCa to discover and validate differentially expressed genes associated with disease aggressiveness. We performed Sample Set Enrichment Analysis (SSEA) and identified genes associated with low versus high Gleason score in the RNA-seq database. Comparing Gleason 6 versus 9+ PCa samples, we identified 99 differentially expressed genes with variable association to Gleason grade as well as robust expression in prostate cancer. The top-ranked novel lncRNA PCAT14, exhibits both cancer and lineage specificity. On multivariate analysis, low PCAT14 expression independently predicts for BPFS (P = .00126), PSS (P = .0385), and MFS (P = .000609), with trends for OS as well (P = .056). An RNA in-situ hybridization (ISH) assay for PCAT14 distinguished benign vs malignant cases, as well as high vs low Gleason disease. PCAT14 is transcriptionally regulated by AR, and endogenous PCAT14 overexpression suppresses cell invasion. Thus, Using RNA-sequencing data we identify PCAT14, a novel prostate cancer and lineage-specific lncRNA. PCAT14 is highly expressed in low grade disease and loss of PCAT14 predicts for disease aggressiveness and recurrence.",
author = "Sudhanshu Shukla and Xiang Zhang and Niknafs, {Yashar S.} and Lanbo Xiao and Rohit Mehra and Marcin Cieślik and Ashley Ross and Edward Schaeffer and Bhavna Malik and Shuling Guo and Freier, {Susan M.} and Bui, {Huynh Hoa} and Javed Siddiqui and Xiaojun Jing and Xuhong Cao and Dhanasekaran, {Saravana M.} and Feng, {Felix Y.} and Chinnaiyan, {Arul M.} and Rohit Malik",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.neo.2016.07.001",
language = "English (US)",
volume = "18",
pages = "489--499",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer

AU - Shukla, Sudhanshu

AU - Zhang, Xiang

AU - Niknafs, Yashar S.

AU - Xiao, Lanbo

AU - Mehra, Rohit

AU - Cieślik, Marcin

AU - Ross, Ashley

AU - Schaeffer, Edward

AU - Malik, Bhavna

AU - Guo, Shuling

AU - Freier, Susan M.

AU - Bui, Huynh Hoa

AU - Siddiqui, Javed

AU - Jing, Xiaojun

AU - Cao, Xuhong

AU - Dhanasekaran, Saravana M.

AU - Feng, Felix Y.

AU - Chinnaiyan, Arul M.

AU - Malik, Rohit

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Rapid advances in the discovery of long noncoding RNAs (lncRNAs) have identified lineage- and cancer-specific biomarkers that may be relevant in the clinical management of prostate cancer (PCa). Here we assembled and analyzed a large RNA-seq dataset, from 585 patient samples, including benign prostate tissue and both localized and metastatic PCa to discover and validate differentially expressed genes associated with disease aggressiveness. We performed Sample Set Enrichment Analysis (SSEA) and identified genes associated with low versus high Gleason score in the RNA-seq database. Comparing Gleason 6 versus 9+ PCa samples, we identified 99 differentially expressed genes with variable association to Gleason grade as well as robust expression in prostate cancer. The top-ranked novel lncRNA PCAT14, exhibits both cancer and lineage specificity. On multivariate analysis, low PCAT14 expression independently predicts for BPFS (P = .00126), PSS (P = .0385), and MFS (P = .000609), with trends for OS as well (P = .056). An RNA in-situ hybridization (ISH) assay for PCAT14 distinguished benign vs malignant cases, as well as high vs low Gleason disease. PCAT14 is transcriptionally regulated by AR, and endogenous PCAT14 overexpression suppresses cell invasion. Thus, Using RNA-sequencing data we identify PCAT14, a novel prostate cancer and lineage-specific lncRNA. PCAT14 is highly expressed in low grade disease and loss of PCAT14 predicts for disease aggressiveness and recurrence.

AB - Rapid advances in the discovery of long noncoding RNAs (lncRNAs) have identified lineage- and cancer-specific biomarkers that may be relevant in the clinical management of prostate cancer (PCa). Here we assembled and analyzed a large RNA-seq dataset, from 585 patient samples, including benign prostate tissue and both localized and metastatic PCa to discover and validate differentially expressed genes associated with disease aggressiveness. We performed Sample Set Enrichment Analysis (SSEA) and identified genes associated with low versus high Gleason score in the RNA-seq database. Comparing Gleason 6 versus 9+ PCa samples, we identified 99 differentially expressed genes with variable association to Gleason grade as well as robust expression in prostate cancer. The top-ranked novel lncRNA PCAT14, exhibits both cancer and lineage specificity. On multivariate analysis, low PCAT14 expression independently predicts for BPFS (P = .00126), PSS (P = .0385), and MFS (P = .000609), with trends for OS as well (P = .056). An RNA in-situ hybridization (ISH) assay for PCAT14 distinguished benign vs malignant cases, as well as high vs low Gleason disease. PCAT14 is transcriptionally regulated by AR, and endogenous PCAT14 overexpression suppresses cell invasion. Thus, Using RNA-sequencing data we identify PCAT14, a novel prostate cancer and lineage-specific lncRNA. PCAT14 is highly expressed in low grade disease and loss of PCAT14 predicts for disease aggressiveness and recurrence.

UR - http://www.scopus.com/inward/record.url?scp=85010792364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010792364&partnerID=8YFLogxK

U2 - 10.1016/j.neo.2016.07.001

DO - 10.1016/j.neo.2016.07.001

M3 - Article

C2 - 27566105

AN - SCOPUS:85010792364

VL - 18

SP - 489

EP - 499

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 8

ER -